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Aim. The aim of this work was to express the human LIF gene in mammalian cells and to study the secretion
of recombinant LIF into culture medium.Methods. Recombinant LIF was detected by Western blot analysis
and immunoprecipitation in culture medium of CHO-K1, L-M (TK
–
) (ins
+
), 293Ò cells, transfected with
recombinant plasmids containing human LIF gene. Results. The recombi- nant plasmids. containing human
gene LIF, were constructed. The cells of three (CHO-K1, L-M (TK
–
) (ins
+
), 293Ò) mammalian lines were
transfected with these plasmids. It was shown that the transfected mammalian cells secreted recombinant
human LIF which was characterized by variable degree of glycosylation including completely glycosylated
form (approximately 68 kD). Ñonclusions. The conditioned medium of developed cell lines can be used as a
sourñe of human recombinant LIF for different purposes, including purification of human recombinant LIF
and as an additional supplement for cell culturing.
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Introduction. Leukemia inhibitory factor (LIF) is
a polyfunctional cytokine of IL-6 family. It affects
different tissues and types of cells, including
hematopoietic, neural and muscle cells, hepatocytes,
adipocytes, osteoblasts and osteoclasts. LIF affects
proliferation of germ cells and maintenance of
pluripotent embryonic stem cells. It plays a key role in
the implantation of a blastocyst, participates in the
hypothalamus-pituitary-adrenal axis activation, and
development of pituitary, kidneys, energetic
homeostasis, etc. [1].
The impact of LIF on the main processes in
different cells is a reason to use this protein as a
growth factor during cultivation of stem cells of
various origin and their directed differentiation into
cells of various types.
LIF is known as an absolutely necessary
component of a medium, required to support
pluripotency of mouse embryonic stem cells. These
cells are widely used for investigations of pluripotency
mechanisms and biology of embryonic stem cells [2,
3]. LIF supports the multiplication of human neural
stem cells, providing their long-term self-renewal (up
to 110 doublings) [4] and keeping their multipotent
properties for a year [5]. It is also added into media for
the cultivation of mesenchymal stem cells (MSC), that
improves their osteogenetic differentiation [6, 7], as
well as for MSC differentiation into cardiomyocytes
[8, 9]. The non-glycosylated, Escherichia coli
expressed, human recombinant LIF has a biological
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activity, which is manifested by its ability to induce
differentiation of murine myeloid leukemic M1 cells
[10]. It is used in investigations in vitro and in vivo,
though the desired results are not always achievable in
vivo [11]. One of the main reasons of such negative
result is the lack of glycosylation of recombinant
proteins. The glycosylation increases protein stability
and its lifetime in bloodstream, influences resistance to
proteases, antigenicity and specific activity which is
important for therapeutic proteins [12]. This fact is the
reason of searching for special ways to increase the
level of glycosylation of recombinant proteins in the
process of their expression in mammalian cells [13,
14]. For cell cultivation in vitro the purified
recombinant growth factors, cytokines, and other
biologically active molecules are added to the medium
or conditioned media are used [15, 16]. Inactivation of
growth factors requires regular replacement of the
medium. Therefore, other approaches to provide
efficient microenvironment for the cultivated cells are
elaborated too, in particular, using immobilized growth
factors [17] and transgenic cell lines as feeder cells
[18–20]. The development of transgenic cell lines of
different origin allows solving a number of tasks,
related to the study of a transgene effect on the
recipient cell. Besides, expression of recombinant
proteins in mammalian cells is a main source of
producing glycosylated proteins. Thus, in 2007 70% of
world production of therapeutic recombinant proteins
were obtained in Chinese hamster cells [21]. Because
of the significance of LIF for investigations in vivo and
in vitro, the aim of this work was to express human
recombinant LIF in the cells of transgenic mammalian
cell lines and to study its secretion into the culture
medium.
Materials and Methods. Plasmids pUC28,
pBluScrII (KS
+), pEGFP-C1; strains of E. coli XL1,
DH10B; cell lines CHO-K1 (Chinese hamster, ovary),
L-M(TK–) (ins+) (mouse, subcutaneous connective
tissue), transfected with recombinant plasmid,
containing human insulin gene, and 293T, which is a
variant of line HEK293 (human embryonic kidney),
expressing large T-antigen SV40 and resistant to G418,
were used in the work.
The isolation of plasmid DNA, treatment with
restriction endonucleases, ligation, obtaining
competent E. coli cells, analysis of recombinant
plasmids were performed by standard methods [22].
The following primers were used to obtain cDNA
LIF: 5’-TCTGAGGTTTCCTCCAAGG-3’ and
5’-TGCTCAGCTTCATCACAGC-3’;
5’-ATGAAGGTCTTGGCGGCAGG-3’ and
5’-ACCTCCTGCTAGAAGGCCTG-3’.
cDNA of LIF gene was obtained by reverse
transcription reaction according to the manufacturer
instructions, using cDNA synthesis kit (Fermentas,
Lithuania). PCR was performed in standard buffer
conditions for Taq and Pfu polymerases using the
optimal program in accordance with specific tasks.
Mammalian cells were transfected with
recombinant plasmids using polyethyleneimine (PEI)
[23]. Cells were kept with the complexes DNA-PEI for
1 hour. Selection of CHO-K1 cells, transfected with
pC1-L, was conducted using G418 (200 ìg/ml). After
transfection with pC1-IL the cells were selected with
hygromycin (200 ìg/ml). L-M(TK–)(ins+) and 293Ò
cells were transfected only with pC1-IL, as they were
resistant to G418. In starting experiments an optimal
concentration of antibiotics required to kill host cells
was determined.
The expression and secretion of LIF into culture
medium were studied by Western-blot analysis and
immunoprecipitation. The cells were grown on DMEM
medium, containing 20% fetal calf serum, washed with
DMEM (serum-free) three times, and then grown in the
same medium during 1.5-2 days. Next, the culture
medium was collected, proteins were precipitated by
10% solution of TCA in the presence of 0.015%
sodium deoxycholate. After protein separation by
SDS-PAGE [24] Western-blot analysis was performed
in accordance with the online protocol of Millipore
company (USA) (millipore.com/immunodetection
/id3/westernblotting), using polyclonal anti-human
LIF antibodies (developed in goat) and anti-goat IgG
peroxidase conjugate (Sigma, USA).
Immunoprecipitation was performed according to
the protocol of Abcam company (USA)
(abcam.com/ps/ pdf/protocols/immunoprecipitation).
1 ml of the conditioned DMEM medium, obtained after
cultivation of 2.5•105 cells, was mixed with 3 ìg of
primary antibodies and incubated for 4 hours while
stirring at 4?C, then 70 ìl of protein G-sepharose were
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added and incubated again (4?C, 4 hours). Samples
were centrifuged, supernatant was removed and protein
G-sepharose was washed three times with the
following buffer: 50 mM tris-HCl, pH 8.0, 150 mM
NaCl, 1% NP-40, 0.1% SDS. 25 ìl of loading buffer
were added to protein G-sepharose and boiled (5 min).
Western-blot analysis was performed after
electrophoresis in SDS-PAGE..
Results and Discussion. At first the LIF coding
sequence with signal sequence [Human LIF gene,
coding LIF with signal peptide, was cloned via
RT-PCR methodology using mRNA, extracted from
human placenta, and corresponding primers. LIF
cDNA, amplified in PCR, was cloned in pBluScrII
(KS+), and its nucleotide sequence was confirmed by
sequencing. Two plasmids – pC1-L and pC1-IL (Fig.1)
– were constructed based on the expression vector for
mammalian cells pEGFP-C1 (Clontech, USA). LIF
gene was introduced to pC1-L under the control of
cytomegalovirus promoter, while a fragment of DNA,
containing IRES (internal ribosome entry site) of
encephalomyocarditis virus and hygromycin resistance
gene were introduced into pC1-IL.
The expression of LIF gene, inserted in these
plasmids, in eukaryotic cells should result in secretion
of the glycosylated protein. LIF has six sites of
glycosylation [25]. The molecular weight (m.w.) of the
protein is in the range from 32 kDa to 73 kDa
depending on the glycosylation degree. Western-blot
analysis of the media, conditioned by the cells of three
cell lines, transfected with recombinant plasmids,
showed that they secreted LIF which was likely
glycosylated to a variable degree. The proteins with
m.w. about 30 kDa, 55 kDa and 68–72 kDA were
identified (Fig.2–4).
The protein with the highest molecular weight
form likely corresponds to completely glycosylated
protein. Bovine serum albumin, presented in the serum,
interfered with the visualization of completely
glycosylated LIF. Due to this fact the LIF secretion was
studied via cultivation of washed cells in serum-free
DMEM. Under these conditions the cells lost their
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Fig.2 Western-blot analysis of conditioned media (1st passage cells): 1 –
CHO-K1 (control, transfection with the vector, serum- free DMEM , 24
hours); 2 – CHO-K1 (transfection with pC1-L, serum-free DMEM, 24
hours); 3 – CHO-K1 (control, transfection with the vector, serum-free
DMEM, 48 hours); 4 – CHO-K1 (transfection with pC1-L, serum-free
DMEM , 48 hours); 5 – molecular weight marker, kDa
viability in 2–3 days and the level of expression of
cellular proteins including recombinant protein
decreased correspondingly. The viability of L-M (TK–)
(ins+) line cells, producing human insulin, was higher
in comparison with CHO-K1 and 293T. Besides, the
controls may have positive signals specified by
endogenous LIF because the degree of homology of
human LIF with murine one is 79%. According to the
analysis of experimental data from different
laboratories, the molecular mass of human LIF isolated
from various cells is diverse. For instance, the
recombinant LIF with m.w. about 45 kDa was
expressed in the Chinese hamster cells [26]. LIF with
m.w. 73 kDa was isolated from the conditioned
medium of the bladder carcinoma cell line 5637 [27].
Other authors isolated LIF with m.w. 43 kDa from the
same source [28], LIF with m.w. 38 kDa was obtained
from the conditioned medium of T-lymphocytes [29].
For Western-blot analysis LIF, secreted into
conditioned medium and concentrated with
immunoprecipitation using protein G-sepharose, was
used. The results obtained with genetically modified
lines CHO-K1, L-M (TK–)(ins+) and 293T, are
presented in Fig.5. The Western-blot analysis revealed
that mobility of some forms of LIF (in particular with
m.w. about 30kDa and 55 kDa) coincided with that of
light and heavy chains of immunoglobulins, added to
the sample during immunoprecipitation. It resulted in
masking some forms of LIF by immunoglobulins. The
level of signals derived from the light and heavy chains
of immunoglobulins in the immunoprecipitation of
conditioned medium by the cells, transfected with
vector plasmids (without LIF gene), was significantly
lower. There was an additional intensive band,
corresponding to the protein with m.w. 65–68 kDa,
which was likely a completely glycosylated form of
LIF, and a less intensive band, corresponding to the
protein with m.w. about 48 kDa. The LIF expression in
cells CHO-K1 (Fig.3, 4) transfected with pC1-L using
G418 selection was more efficient than LIF expression
in cells, transfected with pC1-IL using hygromycin
selection. The efficiency of LIF expression in L-M
(TK–)(ins+) cells, transfected with pC1-IL, was
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Fig.3 Western-blot analysis of
conditioned media (cells of 2nd and
3rd passages, cultivated in serum-free
DMEM for 48 hours); 1 – CHO-K1
(control, transfection with the
vector); 2 – CHO-K1 (transfection
with pC1-L); 3 – CHO-K1
(transfection with pC1-IL); 4 –
molecular weight marker, kDa
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Fig. 4 Western-blot analysis of
conditioned media (cell of 2nd
 4th passages, cultivated in
serum-free DMEM for 48
hours); 1 – L-M(TK–)(ins+)
(control, transfection with the
vector); 2 – L-M(TK–)(ins+)
(transfection with pC1-IL); 3 –
CHO-K1 (control, transfection
with the vector); 4 – CHO-K1
(transfection with pC1-IL); 5 –
CHO-K1 (transfection with
pC1-L); 6 – molecular weight
marker, kDa
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Fig.5 Determination of LIF in conditioned media
(immunoprecipitation) (cells of 2nd – 4th passages, cultivated in
serum-free DMEM for 48 hours, except for L-M(TK–)(ins+)): 1 –
control of immunoprecipitation (immunoprecipitation without
medium); 2 – 293T (control, transfection with the vector); 3 – 293T
(transfection with pC1-IL); 4 – CHO-K1 (control, transfection with
the vector); 5 – CHO-K1 (transfection with pC1-IL); 6 – CHO-K1
(transfection with pC1-L); 7 – L-M (TK–)(ins+) (control,
transfection with the vector); 8 – L-M(TK–)(ins+) (transfection with
pC1-IL, serum-free DMEM, 15 hours); 9 – L-M(TK–)(ins+)
(transfection with pC1-IL, serum- free DMEM, 48 hours); 10 –
molecular weight marker, kDa
sufficiently high like that in CHO-K1 cells, transfected
with pC1-L) ( Fig.4). It may be explained by the fact
that the inhibition of metabolism in insulin-producing
cells in serum-free media is weaker than in CHO-K1
and 293T cells.
Conclusions. The recombinant plasmids pC1-L
and pC1-IL, constructed by us, provide expression and
secretion of human recombinant LIF in the medium of
three mammalian line cells (two murine and one
human) transfected with these plasmids. The
recombinant human LIF produced with mammalian
transgenic cells is glycosylated to different degree,
likely including completely glycosylated form. The
medium conditioned by genetically modified cells may
be used as a source of LIF for growth of different cells
requiring this growth factor as well as for its isolation.
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Ýêñïðåññèÿ è ñåêðåöèÿ ðåêîìáèíàíòíîãî áåëêà
LIF ÷åëîâåêà ãåíåòè÷åñêè ìîäèôèöèðîâàííûìè êëåòêàìè ìëå-
êîïèòàþùèõ
Èíñòèòóò ìîëåêóëÿðíîé áèîëîãèè è ãåíåòèêè ÍÀÍ Óêðàèíû
Óë. Àêàäåìèêà Çàáîëîòíîãî, 150, Êèåâ, Óêðàèíà, 03680
Ðåçþìå
Öåëü ðàáîòû ñîñòîÿëà â ïîëó÷åíèè ýêñïðåññèè ãåíà LIF ÷åëîâå-
êà â ãåíåòè÷åñêè ìîäèôèöèðîâàííûõ êëåòêàõ ìëåêîïèòàþùèõ
è èçó÷åíèè ñåêðåöèè ðåêîìáèíàíòíîãî áåëêà ýòèìè êëåòêàìè â
êóëüòóðàëüíóþ ñðåäó. Ìåòîäû. Äëÿ âûÿâëåíèÿ ðåêîìáèíàí-
òíîãî LIF â êîíäèöèîíèðîâàííîé ñðåäå, ïîëó÷åííîé â ðåçóëüòà-
òå êóëüòèâèðîâàíèÿ êëåòîê, òðàíñôåöèðîâàííûõ ðåêîìáè-
íàíòíûìè ïëàçìèäàìè, ñîäåðæàùèìè ãåí LIF, èñïîëüçîâàëè
Âåñòåðí-áëîò-àíàëèç è èììóíîïðåöèïèòàöèþ. Ðåçóëüòàòû.
Ñêîíñòðóèðîâàííûå ðåêîìáèíàíòíûå ïëàçìèäû îáåñïå÷èâà-
þò åêñïðåññèþ è ñåêðåöèþ ðåêîìáè- íàíòíîãî LIF ÷åëîâåêà
êëåòêàìè òðåõ ëèíèé (CHO-K1, L-M(TK
–
)(ins
+
) è 293Ò), òðàíñ-
ôåöèðîâàííûìè ýòèìè ïëàçìèäàìè. Ñòåïåíü ãëèêîçèëèðîâà-
íèÿ ïðîäóöèðóåìîãî òàêèìè êëåòêàìè ðåêîìáèíàíòíîãî LIF
âàðüèðóåò, ïðè ýòîì íàáëþäàåòñÿ ñåêðåöèÿ ïîëíîñòüþ ãëèêî-
çèëèðîâàííîãî LIF (ñ ìîëåêóëÿðíîé ìàññîé îêîëî 68 êÄà). Âû-
âîäû. Êîíäèöèîíèðîâàííóþ ñðåäó, ïîëó÷åííóþ âñëåäñòâèå
êóëüòèâèðîâàíèÿ òðàíñôåöèðîâàííûõ êëåòîê, ìîæíî èñïîëü-
çîâàòü êàê èñòî÷íèê LIF ÷åëîâåêà äëÿ êóëüòèâèðîâàíèÿ êëå-
òîê, íóæäàþùèõñÿ â ýòîì ðîñòîâîì ôàêòîðå, è äëÿ åãî
âûäåëåíèÿ â ÷èñòîì âèäå.
Êëþ÷åâûå ñëîâà: ðåêîìáèíàíòíûé LIF, ýêñïðåññèÿ, ñåêðå-
öèÿ, òðàíñôåêöèÿ,êëåòî÷íûå ëèíèè
Ñ. Þ. Ðèìàð, Ò. À. Ðóáàí, Ä. Ì. ²ðîäîâ, Â. À. Êîðäþì
Åêñïðåñ³ÿ ³ ñåêðåö³ÿ ðåêîìá³íàíòíîãî á³ëêà LIF ëþäèíè
ãåíåòè÷íî ìîäèô³êîâàíèìè êë³òèíàìè ññàâö³â
Ðåçþìå
Ìåòà. Ìåòà ðîáîòè ïîëÿãàëà â îäåðæàíí³ åêñïðåñ³¿ ãåíà LIF
ëþäèíè â ãåíåòè÷íî ìîäèô³êîâàíèõ êë³òèíàõ ññàâö³â ³ âèâ÷åíí³
ñåêðåö³¿ ðåêîìá³íàíòíîãî á³ëêà öèìè êë³òèíàìè â êóëüòóðàëü-
íå ñåðåäîâèùå. Ìåòîäè. Äëÿ âèçíà÷åííÿ ðåêîìá³íàíòíîãî LIF
â êîíäèö³îíîâàíîìó ñåðåäîâèù³, îäåðæàíîìó â ðåçóëüòàò³
êóëüòèâóâàííÿ êë³òèí, òðàíñôåêîâàíèõ ðåêîìá³íàíòíèìè
ïëàçì³äàìè, ùî ì³ñòÿòü ãåí LIF, âèêîðèñòîâóâàëè Âåñòåðí-
áëîò àíàë³ç òà ³ìóíîïðåöèï³òàö³þ. Ðåçóëüòàòè. Ñêîíñòðóéî-
âàí³ ðåêîìá³íàíòí³ ïëàçì³äè çàáåçïå÷óþòü åêñïðåñ³þ ³ ñåêðå-
ö³þ ðåêîìá³íàíòíîãî LIF ëþäèíè êë³òèíàìè òðüîõ ë³í³é (CHO-
K1, L-M(TK
–
)(ins
+
) ³ 293Ò), òðàíñôåêîâàíèõ öèìè ïëàçì³äàìè.
Ñòóï³íü ãë³êîçèëþâàííÿ ðåêîìá³íàíòíîãî LIF, ïðîäóêîâàíîãî
òàêèìè êë³òèíàìè, âàð³þº, ïðè öüîìó ñïîñòåð³ãàºòüñÿ ñåêðå-
ö³ÿ ïîâí³ñòþ ãë³êîçèëüîâàíîãî LIF (ç ìîëåêóëÿðíîþ ìàñîþ
áëèçüêî 68 êÄà). Âèñíîâêè. Êîíäèö³îíîâàíå ñåðåäîâèùå, îäåð-
æàíå âíàñë³äîê êóëüòèâóâàííÿ òðàíñôåêîâàíèõ êë³òèí, ìîæ-
íà âèêîðèñòîâóâàòè ÿê äæåðåëî LIF ëþäèíè äëÿ êóëüòèâó-
âàííÿ êë³òèí, ÿêèì ïîòð³áåí öåé ðîñòîâèé ôàêòîð, à òàêîæ
äëÿ éîãî âèä³ëåííÿ â î÷èùåíîìó ñòàí³.
Êëþ÷îâ³ ñëîâà: ðåêîìá³íàíòíèé LIF, åêñïðåñ³ÿ, ñåêðåö³ÿ,
òðàíñôåêö³ÿ, êë³òèíí³ ë³í³¿.
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